ChiCTR2100047045 版本V1.2 版本创建时间2022/01/04 14:09:43 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100047045 

最近更新日期:

Date of Last Refreshed on:

2021-12-29 08:38:00 

注册时间:

Date of Registration:

2021-06-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

肠道菌群调控肿瘤免疫治疗的临床研究(观察部分)

Public title:

Gut microbiota intervention influence the efficacy of tumor immunotherapy (Observational study)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

肠道菌群调控肿瘤免疫治疗的临床研究

Scientific title:

Gut microbiota intervention influence the efficacy of tumor immunotherapy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

秦环龙 

研究负责人:

李宁 

Applicant:

Qin Huanlong 

Study leader:

Li Ning 

申请注册联系人电话:

Applicant telephone:

+86 2166302161

研究负责人电话:

Study leader's telephone:

+86 2166302161

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qinhuanlong@tongji.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

liningrigsnju@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市静安区延长中路301号

研究负责人通讯地址:

上海市静安区延长中路301号

Applicant address:

301 Middle Yanchang Road, Jing'an District, Shanghai

Study leader's address:

301 Middle Yanchang Road, Jing'an District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

同济大学附属第十人民医院

Applicant's institution:

The Tenth People′s Hospital, Medical School of Tongji University

研究负责人所在单位:

同济大学附属第十人民医院

Affiliation of the Leader:

The Tenth People′s Hospital, Medical School of Tongji University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SHSY-IEC-4.1/20-33/02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市第十人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Tenth People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-04-09 00:00:00

伦理委员会联系人:

徐辉雄

Contact Name of the ethic committee:

Xu Huixiong

伦理委员会联系地址:

上海市静安区延长路301号

Contact Address of the ethic committee:

301 Yanchang Road, Jing'an District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

同济大学附属第十人民医院

Primary sponsor:

The Tenth People′ s Hospital, Medical School of Tongji University

研究实施负责(组长)单位地址:

上海市静安区延长中路301号

Primary sponsor's address:

301 Yanchang Road, Jing'an District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

同济大学附属第十人民医院

具体地址:

静安区延长中路301号

Institution
hospital:

The Tenth People′ s Hospital, Medical School of Tongji University

Address:

301 Yanchang Road, Jing'an District

经费或物资来源:

上海申康医院发展中心市级医院新兴前沿技术联合攻关项目(立项项目编号: SHDC12019114)

Source(s) of funding:

Clinical Research Plan of SHDC(No.SHDC12019114)

Target disease:

cancer

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

巢式病例-对照研究 

Study design:

Nested case-control study 

研究目的:

主要目的:研究肠道菌群与肿瘤免疫治疗的关系。  

Objectives of Study:

Main purpose: To study the relationship between gut microbiota and cancer immunotherapy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥16周岁;
2.性别不限;
3.因任何原因接受CAR-T或PD-1/PD-L1抑制剂治疗的肿瘤患者。

Inclusion criteria

1. Age ≥ 16 years old;
2. Gender is not limited;
3. Cancer patients receiving car-t or PD-1 / PD-L1 inhibitors for any reason.

排除标准:

因任何原因无法进行疗效评价

Exclusion criteria:

No evaluation of efficacy for any reason

研究实施时间:

Study execute time:

From 2021-06-06 00:00:00 To 2022-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-06-06 00:00:00 To 2022-06-30 00:00:00  

干预措施:

Interventions:

组别:

病例组

样本量:

150

Group:

Case group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

同济大学附属第十人民医院 

单位级别:

三级甲等 

Institution
hospital:

The Tenth People′ s Hospital, Medical School of Tongji University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海市同济医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai Tongji Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肠道菌群

指标类型:

主要指标

Outcome:

Gut microbiome

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

免疫状态

指标类型:

次要指标

Outcome:

Immune status

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤治疗不良反应

指标类型:

次要指标

Outcome:

Side effects of cancer treatment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤疗效相关指标

指标类型:

主要指标

Outcome:

Tumor efficacy related indicators

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

Stool

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 16 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Non-Randomization

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成文章发表后公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The experiment is public after the publication of the article

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-06-07 05:02:46